Latest Breaking News On - Joel russell - Page 9 : vimarsana.com
Valley Economic Alliance Headquarters Building Sells for $7 Million | San Fernando Valley Business Journal
sfvbj.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sfvbj.com Daily Mail and Mail on Sunday newspapers.
AI Firm Ferret Raises $4 Million for Seed Investment | San Fernando Valley Business Journal
sfvbj.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sfvbj.com Daily Mail and Mail on Sunday newspapers.
PS Business Parks Buys Texas Complex for $123 Million | San Fernando Valley Business Journal
sfvbj.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sfvbj.com Daily Mail and Mail on Sunday newspapers.
Staff from Valley facilities of Kaiser Permanente will participate in the health care organization’s 90-second video for “The Rose Parade’s New Year Celebration presented by Honda” on New Year’s Day.
The Pasadena Tournament of Roses will not hold a parade this year due to the coronavirus pandemic. Instead, it will air a two-hour special on television, according to the nonprofit.
Kaiser Permanente, which has produced a float in the parade for 15 years, will provide a video segment with the theme “honoring health care heroes and a healthy, thriving world” that will feature testimonials from doctors, nurses and other employees.
Amgen Inc. has licensed one of its investigational pipeline drugs to Medicines Development for Global Health for the treatment of tuberculosis and leprosy.
Financial terms of the agreement were not disclosed. Medicines Development is a nonprofit biopharmaceutical company in Australia that will assume full responsibility for the further development and commercialization of AMG 634.
Thousand Oaks-based Amgen acquired the drug, called AMG 634, when it bought Otezla from Celgene in 2019 for $13.4 billion.
“Since tuberculosis and erythema nodosum leprosum remain challenging diseases in many countries around the world, Amgen sought an organization that could support the development of AMG 634 to address the global health unmet need,” Dr. David Reese, executive vice president of research and development at Amgen, said in a statement. “MDGH’s track record and experience in product development, global health, and neglected infectious diseases makes them an ideal company to furt